C. A. Bulanhagui

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Antoni Ribas, Luis H. Camacho, Gabriel Lopez‐Berestein et al. · Journal of Clinical Oncology · 2005 · 584 citations

Medicine, Oncology, Pharmacology +17

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

Luis H. Camacho, Scott Antonia, Jeffrey A. Sosman et al. · Journal of Clinical Oncology · 2009 · 314 citations

Pharmacy, Oncology, Pharmacotherapy +17

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

John M. Kirkwood, Paul Lorigan, Peter Hersey et al. · Clinical Cancer Research · 2010 · 240 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Begoña Comı́n-Anduix, Yohan Lee, Jason Jalil et al. · Journal of Translational Medicine · 2008 · 81 citations · Full text

Life Sciences, Immunology, Oncology +17

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

Antoni Ribas, Scott Antonia, Jeffrey A. Sosman et al. · Journal of Clinical Oncology · 2007 · 39 citations

Medicine, Oncology, Pharmacotherapy +16